CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML

From the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Simon Cheesman, MRPharmS, from University College London, London, UK, describes the key outcomes fr... Author: VJOncology Added: 10/15/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts